Clover BioPharma Adds 1,000 Shares via Option Exercise; Outstanding Post-IPO Options Rise to 42.85 Million

Bulletin Express04-09

Hong Kong, 09 April 2026—Clover Biopharmaceuticals, Ltd. reported a minor expansion in its share base for March 2026, driven exclusively by employee option exercises.

The company’s authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to USD 0.20 million.

Issued shares edged up by 1,000 to 1,298.04 million after the exercise of options under the Pre-IPO Share Option Plan. No treasury shares were outstanding, and the firm confirmed full compliance with Hong Kong’s 25% minimum public-float requirement.

Option activity was the primary source of movement: • Pre-IPO Share Option Plan: 1,000 options were exercised, reducing outstanding options to 1.51 million. • Post-IPO Share Option Plan: 10.20 million options were granted, lifting outstanding options by 31% to 42.85 million. The scheme now allows for up to 72.24 million shares to be issued upon future exercises.

The March option exercise generated HKD 8 in proceeds. No warrants, convertible securities, or other share-issuing agreements were reported during the month.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136878317?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136878317","market":"hk","top_or_hot":-1,"title":"Clover BioPharma Adds 1,000 Shares via Option Exercise; Outstanding Post-IPO Options Rise to 42.85 Million","media":"Bulletin Express","content":"<p>Hong Kong, 09 April 2026—Clover Biopharmaceuticals, Ltd. reported a minor expansion in its share base for March 2026, driven exclusively by employee option exercises.</p>\n<p>The company’s authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to USD 0.20 million.</p>\n<p>Issued shares edged up by 1,000 to 1,298.04 million after the exercise of options under the Pre-IPO Share Option Plan. No treasury shares were outstanding, and the firm confirmed full compliance with Hong Kong’s 25% minimum public-float requirement.</p>\n<p>Option activity was the primary source of movement:\n• Pre-IPO Share Option Plan: 1,000 options were exercised, reducing outstanding options to 1.51 million.\n• Post-IPO Share Option Plan: 10.20 million options were granted, lifting outstanding options by 31% to 42.85 million. The scheme now allows for up to 72.24 million shares to be issued upon future exercises.</p>\n<p>The March option exercise generated HKD 8 in proceeds. No warrants, convertible securities, or other share-issuing agreements were reported during the month.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover BioPharma Adds 1,000 Shares via Option Exercise; Outstanding Post-IPO Options Rise to 42.85 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover BioPharma Adds 1,000 Shares via Option Exercise; Outstanding Post-IPO Options Rise to 42.85 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-09 16:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong, 09 April 2026—Clover Biopharmaceuticals, Ltd. reported a minor expansion in its share base for March 2026, driven exclusively by employee option exercises.</p>\n<p>The company’s authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to USD 0.20 million.</p>\n<p>Issued shares edged up by 1,000 to 1,298.04 million after the exercise of options under the Pre-IPO Share Option Plan. No treasury shares were outstanding, and the firm confirmed full compliance with Hong Kong’s 25% minimum public-float requirement.</p>\n<p>Option activity was the primary source of movement:\n• Pre-IPO Share Option Plan: 1,000 options were exercised, reducing outstanding options to 1.51 million.\n• Post-IPO Share Option Plan: 10.20 million options were granted, lifting outstanding options by 31% to 42.85 million. The scheme now allows for up to 72.24 million shares to be issued upon future exercises.</p>\n<p>The March option exercise generated HKD 8 in proceeds. No warrants, convertible securities, or other share-issuing agreements were reported during the month.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"","article_id":"1136878317","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136878317","pubTimestamp":1775724098,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong, 09 April 2026—Clover Biopharmaceuticals, Ltd. reported a minor expansion in its share base for March 2026, driven exclusively by employee option exercises. The company’s authorised share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B"},"translate_title":"Clover BioPharma通过行使期权增持1,000股；IPO后未行使期权增至4285万份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"Hong Kong, 09 April 2026—Clover Biopharmaceuticals, Ltd. reported a minor expansion in its share base for March 2026, driven exclusively by employee option exercises.\nThe company’s authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to USD 0.20 million.\nIssued shares edged up by 1,000 to 1,298.04 million after the exercise of options under the Pre-IPO Share Option Plan. No treasury shares were outstanding, and the firm confirmed full compliance with Hong Kong’s 25% minimum public-float requirement.\nOption activity was the primary source of movement:\n• Pre-IPO Share Option Plan: 1,000 options were exercised, reducing outstanding options to 1.51 million.\n• Post-IPO Share Option Plan: 10.20 million options were granted, lifting outstanding options by 31% to 42.85 million. The scheme now allows for up to 72.24 million shares to be issued upon future exercises.\nThe March option exercise generated HKD 8 in proceeds. No warrants, convertible securities, or other share-issuing agreements were reported during the month.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136878317","isCrawlerRequest":true}